Evidence map›Paper›PMID 41552962›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

Real-World Outcomes With Inetetamab-Based Regimens for HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Analysis in China.

Fangchao Zheng, Jiale Zhang, Dongdong Zhou, Guohua Ren, Ling Qiang, Ting Wang, Fei Pan, Changping Shan, Chongsheng Xia, Fan Yang and 7 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Fangchao ZhengDepartment of Medical Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Jiale ZhangDepartment of Medical Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Dongdong ZhouDepartment of Medical Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Guohua RenDepartment of Medical Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Ling QiangDepartment of Medical Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Ting WangDepartment of Medical Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Fei PanDepartment of Medical Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Changping ShanDepartment of Oncology, Affiliated Hospital of Jining Medical College, Jining, China.
Chongsheng XiaDepartment of Oncology, Affiliated Hospital of Jining Medical College, Jining, China.
Fan YangDepartment of Oncology, Tengzhou Central People's Hospital, Tengzhou, China.
Hongjian WangDepartment of Oncology, Tengzhou Central People's Hospital, Tengzhou, China.
Guozhu LiuDepartment II of Breast, Linyi Cancer Hospital, Linyi, China.
Jingfen WangDepartment II of Breast, Linyi Cancer Hospital, Linyi, China.
Ruimin HuaDepartment of Medical Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Xin DuDepartment of Medical Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Baoxuan ZhangDepartment of Medical Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Huihui LiDepartment of Medical Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionInetetamab has demonstrated favorable efficacy and safety in treating HER2-positive metastatic breast cancer (MBC).MethodsThe multicenter retrospective study enrolled 140 patients with HER2-positive MBC who received inetetamab-based regimens between November 2020 and April 2023. Primary endpoint was progression-free survival (PFS); secondary endpoints included objective response rate (ORR), disease control rate (DCR), and safety.ResultsThe median patient age was 53 (range: 27-90) years, with inetetamab-based regimens administered as first-, second-, or third-line (or later) therapy in 13 (9.3%), 29 (20.7%), and 98 (70.0%) patients, respectively. Median PFS was 6.1 months in the overall population, with an ORR of 35.0% and a DCR of 77.1%. Patients receiving inetetamab as first- or second-line therapy had significantly longer median PFS (14.5 months; 95% CI, 9.5-19.5) than those receiving it as third-line or later therapy (4.8 months; 95% CI, 4.2-5.3;

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesAdultAgedAged, 80 and overChinaFemaleHumansMiddle AgedNeoplasm MetastasisRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesHER2-positive metastatic breast cancerInetetamabReal-world evidenceTreatment line

Identifiers

PMID41552962
PMCPMC12816558

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.